Ocugen's Stock Tests Critical Floor as Analysts Hold Firm on $9.75 Target Ahead of Stifel Forum Pitch

Ocugen trades at a 93% discount to the $9.75 analyst consensus as its gene therapy pipeline awaits clinical milestones. Recent financing extends cash runway to 2028; key investor event on May 26.

The chasm between where Ocugen's shares trade and where analysts see them heading has rarely been wider. Four analysts cover the Pennsylvania-based biotech with unbroken bullishness — 75% rate it a "Strong Buy" and the rest a "Buy" — and their average price target stands at $9.75. Yet the stock closed Thursday at $1.35 on U.S. exchanges, a 93% discount to that consensus that underscores just how much the market is discounting the company's gene therapy pipeline until it delivers tangible clinical milestones.

Technically, the equity is clinging to a support zone that could determine its near-term direction. After sliding roughly 24% below its 50-day moving average and losing more than a fifth of its value in the past month, Ocugen's shares ended the week at $1.35 after a 0.7% daily dip, with the intraday range narrowing to $1.33–$1.38. The relative strength index is hovering near oversold territory, and a pivot low on May 19 generated a technical buy signal. If that level fails, the next line of defense sits around $1.28 — a threshold that may be tested if the upcoming investor event fails to spark renewed conviction.

Financially, the company has bought itself breathing room. Ocugen closed a $130 million convertible note issuance carrying a 6.75% coupon and maturing in 2034, using roughly $32.7 million of the proceeds to retire its existing Avenue credit facility, which had carried a 12.5% interest rate. The refinancing slashed annual interest costs and, according to management, extends the cash runway into 2028. At the end of the first quarter, the company held $31.9 million in cash and equivalents — a figure that the convertible will supplement for the remainder of the year.

The first-quarter results themselves were mixed. Ocugen reported a net loss of $19.18 million, or $0.06 per share, coming in 16% below the consensus estimate of a $0.05 loss. Revenue from collaboration agreements reached $1.53 million, however, topping the recently revised analyst forecast of $1.43 million — a rare bright spot in an otherwise cash-intensive period driven by clinical development.

On the pipeline front, all eyes are on the modifier gene therapy platform. The most advanced program is OCU400, now in a Phase 3 study called liMeliGhT for retinitis pigmentosa, alongside OCU410 in a Phase 2 trial (ArMaDa) targeting geographic atrophy and OCU410ST for Stargardt disease. The company has set a goal of submitting three Biologics License Applications by 2028. Management is scheduled to present at the Stifel 2026 Virtual Ophthalmology Forum on May 26 at 10:30 a.m. EDT, where updates on these programs will be the centerpiece.

Analysts are betting that clinical progress will eventually close the gap between the share price and the $9.75 target, but the market remains skittish. A 4.62% bounce on Wednesday materialized on lower-than-average volume, which technical models interpreted as a sign of persistent selling pressure rather than a conviction reversal. With the stock trading near a critical support zone and a major catalyst just days away, the next few sessions will show whether the bulls can defend the floor — or whether the gap to $1.28 becomes the next reality.